Best Stocks Under $50.00 for 2018

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs and the price-to-earnings ratios of most S&P 500 companies look very expensive. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $50.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $50.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks and bitcoin stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $50.00 or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Advanced Disposal Services (NYSE:ADSW)

Stock Price: $26.76
Market Cap: $2.37 billion
P/E Ratio: 47.0
Consensus Rating: Buy
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $28.00 (4.6% Upside)

Advanced Disposal Services logoAdvanced Disposal Services, Inc. provides non-hazardous solid waste collection, transfer, recycling, and disposal services. It is involved in the curbside collection of residential refuse from small carts or containers into collection vehicles for transport to a disposal/recycling site. The company also supplies commercial and industrial customers with waste containers; rents or sells compactors to large waste generators; and provides roll-off containers, as well as waste collection, transportation, and disposal services to construction and demolition sites. In addition, it offers landfill disposal services; and manages or operates recycling facilities that collect, process, and sell old corrugated cardboard, old newspaper, mixed paper, aluminum, glass, and other materials, as well as provides customer services. Further, the company engages in trucking activities; and landfill gas-to-energy operations at municipal solid waste landfills, as well as manages third-party owned landfills. It serves approximately 2.8 million residential customers; 200,000 commercial and industrial customers; and 800 municipalities in the Southeast, Midwest, and Eastern regions of the United States, as well as the Commonwealth of the Bahamas. The company was formerly known as ADS Waste Holdings, Inc. and changed its name to Advanced Disposal Services, Inc. in January 2016. Advanced Disposal Services, Inc. was founded in 2000 and is headquartered in Ponte Vedra, Florida.
#2 - Ichor (NASDAQ:ICHR)

Stock Price: $17.01
Market Cap: $414.35 million
P/E Ratio: 7.1
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $38.60 (126.9% Upside)

Ichor logoIchor Holdings Ltd. engages in the design, engineering, and manufacturing of fluid delivery subsystems for semiconductor capital equipment. It offers gas and chemical delivery systems and manufactures components for internal use in fluid delivery systems and for direct sales of the customers. The gas delivery subsystems deliver, monitor, and control precise quantities of the specialized gases used in semiconductor manufacturing processes such as etch and deposition. The chemical delivery subsystems blend and dispense the reactive liquid chemistries used in semiconductor manufacturing processes such as chemical-mechanical planarization, electroplating, and cleaning. The company was founded on January 30, 2012 and is headquartered in Fremont, CA.
#3 - Ra Pharmaceuticals (NASDAQ:RARX)

Stock Price: $16.64
Market Cap: $538.14 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $22.75 (36.7% Upside)

Ra Pharmaceuticals logoRa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
#4 - Construction Partners (NASDAQ:ROAD)

Stock Price: $10.19
Market Cap: $521.39 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $15.10 (48.2% Upside)

Construction Partners logoConstruction Partners, Inc., an infrastructure and road construction company, provides construction products and services to public and private sectors. Its services cover construction of highways, roads, bridges, airports, and commercial and residential sites. The company provides site development, paving, utility and drainage systems, as well as supplies hot mix asphalt. It serves customers primarily in Alabama, Florida, Georgia, North Carolina, and South Carolina. The company was formerly known as SunTx CPI Growth Company, Inc. and changed its name to Construction Partners, Inc. in September 2017. Construction Partners, Inc. was founded in 2001 and is headquartered in Dothan, Alabama.
#5 - Mesa Air Group (NASDAQ:MESA)

Stock Price: $13.86
Market Cap: $320.48 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $17.80 (28.4% Upside)

Mesa Air Group logoMesa Air Group, Inc. operates as the holding company for Mesa Airlines, Inc., which provides regional air services under capacity purchase agreements with the American Airlines and the United Airlines. As of March 31, 2018, it operated 145 aircraft with approximately 610 daily departures to 110 cities in the United States, Canada, Mexico, the Bahamas, and Cuba. Mesa Air Group, Inc. was founded in 1982 and is headquartered in Phoenix, Arizona.
#6 - Ladder Capital (NYSE:LADR)

Stock Price: $17.38
Market Cap: $1.93 billion
P/E Ratio: 12.8
Dividend Yield: 7.48 %
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $17.2857 (-0.5% Upside)

Ladder Capital logoLadder Capital Corp operates as a real estate investment trust in the United States. The company operates through three segments: Loans, Securities, and Real Estate. The Loans segment originates conduit first mortgage loans that are secured by cash-flowing commercial real estate; and originates and invests in balance sheet first mortgage loans secured by commercial real estate properties that are undergoing transition, including lease-up, sell-out, and renovation or repositioning. It also invests in note purchase financings, subordinated debt, mezzanine debt, and other structured finance products related to commercial real estate. The Securities segment invests in commercial mortgage-backed securities and the U.S. Agency Securities. The Real Estate segment owns and invests in a portfolio of commercial and residential real estate properties, such as leased properties, office buildings, a warehouse, and condominium units. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. Ladder Capital Corp was founded in 2008 and is headquartered in New York, New York.
#7 - Malibu Boats (NASDAQ:MBUU)

Stock Price: $45.79
Market Cap: $944.46 million
P/E Ratio: 18.2
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $56.6667 (23.8% Upside)

Malibu Boats logoMalibu Boats, Inc. designs, manufactures, distributes, markets, and sells recreational powerboats. The company offers performance sport boats under the Malibu and Axis brand names; and sterndrives and outboard boats under the Cobalt brand name. Its boats are used for water sports, including water skiing, wakeboarding, and wake surfing, as well as general recreational boating. The company also offers various accessories and aftermarket parts. It operates through a network of independent dealers in North America, South America, Europe, Asia, Australia, and New Zealand markets. Malibu Boats, Inc. was founded in 1982 and is based in Loudon, Tennessee.
#8 - Wyndham Hotels & Resorts (NYSE:WH)

Stock Price: $48.00
Market Cap: $5.02 billion
Dividend Yield: 1.99 %
Consensus Rating: Buy
Ratings Breakdown: 8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $73.2857 (52.7% Upside)

Wyndham Hotels & Resorts logoWyndham Hotels & Resorts, Inc. operates as a hotel franchisor worldwide. The company licenses its hotel brands, including Super 8, Days Inn, Ramada, Microtel Inn & Suites, La Quinta, Wingate, AmericInn, Hawthorn Suites, The Trademark Collection, and Wyndham to hotel owners in approximately 80 countries. Its Hotel Franchising segments licenses its lodging brands and provides related services to third-party hotel owners and others. The company's Hotel Management segment provides hotel management services for full-service and limited service hotels. As of May 31, 2018, Wyndham Hotels & Resorts, Inc. operated a portfolio of 20 hotel brands with approximately 9,000 franchised hotels with 790,000 rooms. The company was founded in 2017 and is headquartered in Parsippany, New Jersey. Wyndham Hotels & Resorts, Inc. is a subsidiary of Wyndham Worldwide Corporation.
#9 - Boston Scientific (NYSE:BSX)

Stock Price: $36.54
Market Cap: $50.53 billion
P/E Ratio: 26.3
Consensus Rating: Buy
Ratings Breakdown: 21 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $38.4091 (5.1% Upside)

Boston Scientific logoBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
#10 - Zogenix (NASDAQ:ZGNX)

Stock Price: $41.52
Market Cap: $1.48 billion
P/E Ratio: -10.3
Consensus Rating: Buy
Ratings Breakdown: 9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $74.7778 (80.1% Upside)

Zogenix logoZogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
#11 - Ferro (NYSE:FOE)

Stock Price: $17.32
Market Cap: $1.46 billion
P/E Ratio: 13.4
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $28.50 (64.5% Upside)

Ferro logoFerro Corporation produces specialty materials in the United States and internationally. It operates through four business units: Tile Coating Systems; Porcelain Enamel; Performance Colors and Glass; and Color Solutions. The company offers frits, porcelain and other glass enamels, glazes, stains, decorating colors, pigments, inks, polishing materials, dielectrics, electronic glasses, and other specialty coatings. Its products are used in appliances, automobiles, building and renovation, electronics, household furnishings, industrial products, packaging, and sanitary applications. The company markets and sells its products directly, as well as through agents and distributors. Its customers include manufacturers of ceramic tile, construction materials, automobile parts, automobiles, architectural and container glass, and electronic components and devices. Ferro Corporation was founded in 1919 and is headquartered in Mayfield Heights, Ohio.
#12 - At Home Group (NYSE:HOME)

Stock Price: $26.01
Market Cap: $1.65 billion
P/E Ratio: 44.1
Consensus Rating: Buy
Ratings Breakdown: 9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $42.00 (61.5% Upside)

At Home Group logoAt Home Group Inc. operates home decor superstores in the United States. The company's stores offer approximately 50,000 items, such as accent furniture, mirrors, patio cushions, rugs and wall arts, artificial flowers and trees, bedding and bath products, candles, garden and outdoor décor, holiday accessories, home organization, pillows, pottery, vases, and window treatments. As of October 10, 2018, it operated approximately 170 stores in 36 states. The company was founded in 1979 and is headquartered in Plano, Texas.
#13 - Golar LNG (NASDAQ:GLNG)

Stock Price: $27.21
Market Cap: $2.75 billion
Dividend Yield: 1.84 %
Consensus Rating: Buy
Ratings Breakdown: 11 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $36.40 (33.8% Upside)

Golar LNG logoGolar LNG Limited, a midstream liquefied natural gas (LNG) company, engages in the transportation, regasification, and liquefaction of LNG. It operates through three segments: Vessel operations, Floating Liquefaction Natural Gas Vessel (FLNG), and Power. The company engages in the acquisition, ownership, operation, and chartering of LNG carriers and floating storage regasification units (FSRUs); and the development of LNG projects. As of April 6, 2018, Golar LNG Limited, together with Golar LNG Partners LP and Golar Power Limited, owned and operated a fleet of 26 vessels, including 18 LNG carriers, 7 FSRUs, and 1 FLNG. The company was founded in 1946 and is headquartered in Hamilton, Bermuda.
#14 - OceanFirst Financial (NASDAQ:OCFC)

Stock Price: $25.57
Market Cap: $1.24 billion
P/E Ratio: 14.1
Dividend Yield: 2.35 %
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $34.00 (33.0% Upside)

OceanFirst Financial logoOceanFirst Financial Corp. operates as the holding company for OceanFirst Bank N.A. that provides a range of community banking services. The company offers various deposit products to retail, government, and business customers, including money market accounts, savings accounts, interest-bearing checking accounts, non-interest-bearing accounts, and time deposits. It also provides commercial real estate, multi-family mortgage, and land loans; fixed-rate and adjustable-rate mortgage loans that are secured by one-to-four family residences; consumer loans, such as home equity loans and lines of credit, overdraft line of credit, loans on savings accounts, and other consumer loans; and commercial and industrial loans, and lines of credit. In addition, the company invests in mortgage-backed securities, securities issued by the U.S. Government and agencies, corporate securities, and other investments. Further, it offers bankcard and wealth management services; and sells alternative investment products and life insurance products. The company operates through an administrative/branch office located in Toms River, New Jersey; and 45 additional branch offices and 3 deposit production facilities in central and southern New Jersey, as well as operates a wealth management office in Ocean County, and commercial loan production offices in the Philadelphia area and Atlantic, Cape May, and Mercer Counties in New Jersey. OceanFirst Financial Corp. was founded in 1902 and is based in Toms River, New Jersey.
#15 - Limelight Networks (NASDAQ:LLNW)

Stock Price: $4.25
Market Cap: $478.73 million
P/E Ratio: 141.7
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $6.30 (48.2% Upside)

Limelight Networks logoLimelight Networks, Inc. provides content delivery and related services and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers services and solutions for businesses to deliver their digital content across Internet, mobile, and social channels. It provides Orchestrate Platform, a suite of integrated services comprising content delivery, video content management, Website and Web application acceleration, Website and content security, and cloud storage services. The company also offers professional services and other infrastructure services, such as transit and rack space services. It serves media companies operating in the television, music, radio, newspaper, magazine, movie, game, software, and social media industries, as well as enterprises, technology companies, and government entities conducting business online. Limelight Networks, Inc. was founded in 2001 and is headquartered in Tempe, Arizona.
#16 - CRH (NYSE:CRH)

Stock Price: $28.30
Market Cap: $23.74 billion
Dividend Yield: 1.29 %
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $37.00 (30.7% Upside)

CRH logoCRH plc, through its subsidiaries, manufactures and distributes building materials. It operates through six segments: Europe Heavyside, Europe Lightside, Europe Distribution, Americas Materials, Americas Products, and Asia. The company manufactures and supplies cement, aggregates, asphalt, lime, and readymixed concrete and concrete products; and construction accessories, network access and perimeter protection products, shutters and awnings, and architectural products. It also produces and sells concrete masonry and hardscapes, packaged lawn and garden products, packaged cement mixes, and glass and aluminum glazing systems, as well as fencing, utility, drainage, and structural precast products; and provides asphalt paving services. In addition, the company sells and distributes bricks, cement, sanitary, heating, plumbing, and other building products to small and medium-sized builders through 352 locations; general public through 198 retail locations; and plumbers, as well as heating, gas, water, and ventilation technicians through 134 showrooms. It operates primarily in Western Europe and North America, as well as in Eastern Europe, the Philippines, Brazil, China, and India. CRH plc was founded in 1936 and is headquartered in Dublin, Ireland.
#17 - Altra Industrial Motion (NASDAQ:AIMC)

Stock Price: $35.60
Market Cap: $1.05 billion
P/E Ratio: 15.3
Dividend Yield: 1.91 %
Consensus Rating: Buy
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $52.75 (48.2% Upside)

Altra Industrial Motion logoAltra Industrial Motion Corp. designs, produces, and markets mechanical power transmission components worldwide. The company operates through three segments: Couplings, Clutches and Brakes; Electromagnetic Clutches and Brakes; and Gearing. It offers coupling products under the Ameridrives, Bibby, Lamiflex, TB Wood's, Huco Dynatork, Guardian, and Stromag brands for food processing, oil and gas, power generation, material handling, medical, metals, mining, and mobile off-highway markets; and heavy duty clutches and brakes under the Wichita Clutch, Twiflex, Industrial Clutch, Svendborg Brakes, and Stromag brands for use in metal forming, oil and gas drilling platforms, mining, material handling, marine, and wind turbine applications. The company also provides overrunning clutches under the Formsprag, Marland, and Stieber brands used in conveyors, gear reducers, hoists and cranes, mining machinery, machine tools, paper machinery, and other specialty machinery, as well as aerospace and defense market; and engineered belted drives under the TB Wood's brand for aggregate, energy, chemical, and material handling markets. In addition, it offers electromagnetic clutches and brakes under the Warner Electric, Inertia Dynamics, Matrix, and Stromag brands for material handling, forklift, elevator, medical mobility, mobile off-highway, baggage handling, and plant productivity applications, as well as for walk-behind mowers, residential lawn tractors, and commercial mowers; gears under the Boston Gear, Nuttall Gear, Delroyd, and Bauer Gear Motor brands that are used in industrial, material handling, mixing, transportation, and food processing applications; and engineered bearing assemblies under the Kilian brand name for use in general industrial and automotive markets. The company was formerly known as Altra Holdings, Inc. and changed its name to Altra Industrial Motion Corp. in November 2013. The company was founded in 2004 and is headquartered in Braintree, Massachusetts.
#18 - Capstone Turbine (NASDAQ:CPST)

Stock Price: $0.89
Market Cap: $57.13 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $2.30 (158.4% Upside)

Capstone Turbine logoCapstone Turbine Corporation develops, manufactures, markets, and services microturbine technology solutions for use in stationary distributed power generation applications worldwide. It offers microturbine units, components, and various accessories for applications, including cogeneration comprising combined heat and power (CHP) and integrated CHP, as well as combined cooling, heat, and power; and renewable energy, natural resources, and critical power supply. The company's microturbines are also used as battery charging generators for hybrid electric vehicle applications. It also provides various accessories, including rotary gas compressors with digital controls; heat recovery modules for CHP applications; dual mode controllers that allow automatic transition between grid connect and stand-alone modes; batteries with digital controls for stand-alone or dual-mode operations; batteries with digital controls; power servers for multipacked installations; protocol converters for Internet access; packaging options; and miscellaneous parts, such as frames, exhaust ducting, backflow dampers, and installation hardware. In addition, the company remanufactures microturbine engines; and provides after-market parts and services. It markets and sells its products primarily through distributors and original equipment manufacturers. Capstone Turbine Corporation was founded in 1988 and is headquartered in Van Nuys, California.
#19 - Catalyst Pharmaceuticals (NASDAQ:CPRX)

Stock Price: $3.31
Market Cap: $339.60 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $6.00 (81.3% Upside)

Catalyst Pharmaceuticals logoCatalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3. The company is also developing CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms; and CPP-109, a vigabatrin tablet. It has license agreements with Northwestern University, New York University and the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
#20 - CTI BioPharma (NASDAQ:CTIC)

Stock Price: $1.93
Market Cap: $111.92 million
P/E Ratio: -1.6
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $6.20 (221.2% Upside)

CTI BioPharma logoCTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. The company's product candidate in pipeline includes tosedostat, a novel oral, once-daily aminopeptidase inhibitor for patients with acute myeloid leukemia. It has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; Teva Pharmaceutical Industries Ltd; University of Vermont; S*BIO Pte Ltd; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel